The prevalent inflammatory picture in mild eosinophilic allergic and nonallergic asthma is now established. Neutrophilic asthma and the underlying inflammatory responses after allergen challenge in mild asthma are also established. Paucigranulocytic asthma and airway remodeling occurring in mild to severe forms of the disease are further recent acquisitions. These advances have led to a better definition of the therapeutic strategy with inhaled corticosteroids (ICS) and long acting β2 agonists (LABA) and to innovative therapies with monoclonal antibodies targeted against key effector molecules. This review discusses some aspects of asthma pathology in relation to therapeutic progress.
Pathology of Asthma / Di Stefano, A.; Carriero, V.; Bertolini, F.; Caramori, G.; Ricciardolo, F. L. M.. - 2:(2022), pp. 296-307. [10.1016/B978-0-08-102723-3.00099-8]
Pathology of Asthma
Caramori G.Membro del Collaboration Group
;
2022-01-01
Abstract
The prevalent inflammatory picture in mild eosinophilic allergic and nonallergic asthma is now established. Neutrophilic asthma and the underlying inflammatory responses after allergen challenge in mild asthma are also established. Paucigranulocytic asthma and airway remodeling occurring in mild to severe forms of the disease are further recent acquisitions. These advances have led to a better definition of the therapeutic strategy with inhaled corticosteroids (ICS) and long acting β2 agonists (LABA) and to innovative therapies with monoclonal antibodies targeted against key effector molecules. This review discusses some aspects of asthma pathology in relation to therapeutic progress.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
